Showing 1 to 10 of 44 Clinical Trials
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
---|---|---|---|
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
SGN35-033 (KEYNOTE B81) NCT04609566 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Head and Neck Melanoma Non Small Cells - Lung |
Dr. Wilson Miller Daria Krutauz 514-340-8222 poste 24301 Rim Hojeij 514-340-8222 poste 26187 |
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 ![]() |
CISSS DE LA MONTEREGIE-CENTRE
![]() |
Melanoma Non Small Cells - Lung |
Dr. Nathalie Daaboul Marilyn Tessier 450-466-5000 poste 7691 |
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Melanoma Non Small Cells - Lung |
Dr. Bertrand Routy Wiam Belkaid 514-890-8000 |
A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial
STABLE-MATES Trial (JoLT-Ca) NCT02468024 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Édith Filion Dr. Moishe Liberman Adeline Jouquan 514-890-8000 poste 26214 |
Study of the function and phenotype of tumor infiltrating lymphocytes in non-small cell lung cancer (Main study)
QC-CAPRION n.d. ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Moishe Liberman Adeline Jouquan 514-890-8000 poste 26214 |
A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer
SGNB6A-002 (Be6A Lung-01) NCT06012435 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Normand Blais Chantal Gosselin 514-890-8000 poste 24892 |
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
M18-868 NCT04928846 ![]() |
CISSS DE LA MONTEREGIE-CENTRE
![]() |
Non Small Cells - Lung |
Dr. Nathalie Daaboul Marie-Ève Yelle 450-466-5000 poste 3281 |
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Krascendo 170 NCT05789082 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Non Small Cells - Lung |
Dr. Jennifer Friedmann Chadi Zakaria 514-340-8222 poste 28326 |
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ?50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
TROPION-Lung08 NCT05215340 ![]() |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
![]() |
Non Small Cells - Lung |
Dr. Michael Palumbo Sabrina Sanzari 514-252-6000 poste 6677 |
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
eVOLVE-Lung02 NCT05984277 ![]() |
CISSS DE CHAUDIERE-APPALACHES
![]() |
Non Small Cells - Lung |
Dr. Marie-Ève Boucher Pierre Bédard 418-835-7121 |